Samsung Biologics to buy Switzerland's PolyPeptide Group in $1.8 billion all-cash deal

• Samsung Biologics will pay 44.31 Swiss francs per share in an all-cash tender offer totaling 1.46 billion Swiss francs ($1.8 billion)
• The acquisition adds peptide-based drug manufacturing capabilities to Samsung's existing antibody drug portfolio, targeting the fast-growing GLP-1 obesity and diabetes treatment market
• PolyPeptide Group brings a global manufacturing network across Sweden, Belgium, France, the U.S., and India, with experience developing over 1,000 therapeutic peptides since its 1996 spinoff from Ferring

Summary: Samsung Biologics Acquires PolyPeptide Group for $1.8 Billion

Deal Overview:

Samsung Biologics has announced an all-cash acquisition of Switzerland's PolyPeptide Group for 1.46 billion Swiss francs ($1.8 billion), marking South Korea's largest biopharmaceutical M&A transaction. The public tender offer prices shares at 44.31 Swiss francs each, with completion expected by year-end.

Strategic Rationale:

The acquisition enables Samsung Biologics to expand beyond its core antibody drugs and antibody-drug conjugates into peptide therapeutics, one of the fastest-growing biopharmaceutical segments. The move specifically targets the booming GLP-1 weight-loss and diabetes drug market, where peptide-based treatments mimic natural hormones to reduce appetite and regulate blood sugar.

Target Company Profile:

PolyPeptide Group, headquartered in Baar, Switzerland, specializes in peptide-based active pharmaceutical ingredients. Spun off from Ferring in 1996, the company has developed and produced over 1,000 therapeutic peptides and operates facilities across Sweden, Belgium, France, the U.S., and India, encompassing R&D, development, and commercial manufacturing capabilities.

Market Implications:

This transaction reflects the pharmaceutical industry's aggressive pursuit of exposure to the lucrative obesity treatment market. Samsung Biologics aims to diversify its portfolio and meet surging client demand for peptide-based GLP-1 therapies. The deal significantly expands the company's global manufacturing footprint and therapeutic capabilities, positioning it to capitalize on the explosive growth in weight-loss medications. PolyPeptide's board has endorsed the offer as compelling for shareholders.